WVE

WAVE LIFE SCIENC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.10
-0.07
-0.76%
After Hours: 9.15 +0.05 +0.55% 16:15 08/14 EDT
OPEN
9.20
PREV CLOSE
9.17
HIGH
9.24
LOW
8.96
VOLUME
180.64K
TURNOVER
--
52 WEEK HIGH
39.98
52 WEEK LOW
6.61
MARKET CAP
331.73M
P/E (TTM)
-1.6068
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average WVE stock price target is 16.71 with a high estimate of 21.00 and a low estimate of 8.00.

EPS

WVE News

More
WAVE Life Sciences Pte. Ltd. (WVE) Q2 2020 Earnings Call Transcript
On the call with me today are Dr. Paul Bolno, our President and CEO; Dr. Mike Panzara, our Chief Medical Officer, Head of Therapeutics Discovery and Development; David Gaiero, Interim CFO; Dr. Chandra Vargeese, Chief Technology Officer; and Dr. Ken Rhodes, SVP
Motley Fool · 4d ago
Wave Life Sciences (WVE) Reports Q2 Loss, Lags Revenue Estimates
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -11.65% and -57.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 5d ago
WAVE Life Sciences: Q2 Earnings Insights
Shares of WAVE Life Sciences (NASDAQ:WVE) moved higher by 1% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share were up 5.74% over the past year to ($1.15), which missed the estimate of ($0.97).Revenue of $3,027,00
Benzinga · 5d ago
WAVE Life Sciences Q2 EPS $(1.15) Misses $(0.97) Estimate, Sales $3.03M Miss $5.65M Estimate
WAVE Life Sciences (NASDAQ:WVE) reported quarterly losses of $(1.15) per share which missed the analyst consensus estimate of $(0.97) by 18.56 percent. This is a 5.74 percent increase over losses of $(1.22) per share
Benzinga · 5d ago
Wave Life Sciences Reports Second Quarter 2020 Financial Results and Provides Business Update
Data from 32 mg cohorts of both PRECISION-HD trials and PRECISION-HD OLE trials expected in 1Q 2021 C9orf72 and SNP3 clinical trial applications on track to be submitted in 4Q 2020ADAR editing advancing with additional in vivo data expected at upcoming Analys
GlobeNewswire · 5d ago
Wave Life Sciences to Highlight PRISM Platform Advancements and Preclinical Neurology Pipeline During Analyst and Investor Research Webcast
Neurology pipeline discussion will include new preclinical data for C9orf72 program for ALS and FTDPlatform advancements to be shared include new in vivo RNA editing data Live webcast scheduled for Tuesday, August 25th at 10:00 a.m. ETCAMBRIDGE, Mass., Aug. 0
GlobeNewswire · 08/06 12:00
Will Wave Life Sciences (WVE) Report Negative Earnings Next Week? What You Should Know
Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 08/03 16:31
Wave Life Sciences to Webcast Conference Call of Second Quarter 2020 Financial Results on August 10, 2020
CAMBRIDGE, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management wil
GlobeNewswire · 07/27 20:05

Industry

Biotechnology & Medical Research
-0.54%
Pharmaceuticals & Medical Research
-0.38%

Hot Stocks

Symbol
Price
%Change

About WVE

WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. The nucleic acid therapeutics, which the Company is developing are stereopure. A stereopure oligonucleotide includes molecules with atoms arranged in three-dimensional orientations at each linkage. The Company has three programs in Huntington's disease (HD) and Duchenne Muscular Dystrophy (DMD), and three additional development candidates.
More

Webull offers kinds of Wave Life Sciences Ltd stock information, including NASDAQ:WVE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, WVE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading WVE stock methods without spending real money on the virtual paper trading platform.